SCHEMBL1721784

SCHEMBL1721784

CCN(C)C(=O)c1ncc(Oc2cc(C(=O)Nc3ccn(C)n3)cc3oc(C)cc23)cn1

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCK P35557 20/20 0.66
KCNH2 Q12809 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720870 0.93 GCK (0.74) GCKKCNH2
SCHEMBL1721794 0.85 GCK (0.85) GCKKCNH2
SCHEMBL10257303 0.82 GCK (0.68) GCKKCNH2
SCHEMBL644979 0.80 GCK (0.67) GCKKCNH2
SCHEMBL1720187 0.79 GCK (0.57) GCKKCNH2
SCHEMBL643719 0.78 GCK (0.71) GCKKCNH2
SCHEMBL14995964 0.78 GCK (0.81) GCKKCNH2
SCHEMBL646384 0.77 GCK (0.60) GCKKCNH2
Nerigliatin SCHEMBL1720691 0.77 GCK (1.00) GCKKCNH2
Nerigliatin SCHEMBL29411291 0.77 GCK (1.00) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604604-A1 Benzofuranyl derivatives used as glucokinase inhibitors Pfizer Inc (US) 2013-06-19 EP claimed
US-20100234285-A1 Benzofuranyl Derivatives PFIZER INC 2010-09-16 US claimed
US-8735396-B2 Benzofuranyl derivatives PFIZER INC. (US) 2014-05-27 US disclosed
US-8735396-B2 Benzofuranyl derivatives PFIZER INC. (US) 2014-05-27 US disclosed
US-8735396-B2 Benzofuranyl derivatives PFIZER INC. (US) 2014-05-27 US disclosed
US-20130252973-A1 Benzofuranyl Derivatives PFIZER INC. (US) 2013-09-26 US disclosed
US-20130252973-A1 Benzofuranyl Derivatives PFIZER INC. (US) 2013-09-26 US disclosed
US-20130252973-A1 Benzofuranyl Derivatives PFIZER INC. (US) 2013-09-26 US disclosed
EP-2406253-B1 BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS PFIZER (US) 2013-07-03 EP disclosed
EP-2604604-A1 Benzofuranyl derivatives used as glucokinase inhibitors Pfizer Inc (US) 2013-06-19 EP disclosed
US-8455496-B2 Benzofuranyl derivatives PFIZER INC. (US) 2013-06-04 US disclosed
US-8455496-B2 Benzofuranyl derivatives PFIZER INC. (US) 2013-06-04 US disclosed
US-8455496-B2 Benzofuranyl derivatives PFIZER INC. (US) 2013-06-04 US disclosed
EP-2406253-A1 BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS Pfizer Inc. (US) 2012-01-18 EP disclosed
WO-2010103437-A1 BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS PFIZER INC. (US) 2010-09-16 WO disclosed
US-20100234285-A1 Benzofuranyl Derivatives PFIZER INC 2010-09-16 US disclosed
US-20100234285-A1 Benzofuranyl Derivatives PFIZER INC 2010-09-16 US disclosed
US-20100234285-A1 Benzofuranyl Derivatives PFIZER INC 2010-09-16 US disclosed
WO-2010103437-A1 BENZOFURANYL DERIVATIVES USED AS GLUCOKINASE INHIBITORS PFIZER INC. (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234285-A1 Benzofuranyl Derivatives GCK, GCKR, GALK1 GCK 1/4885KCNH2 1501/4885
US-20130252973-A1 Benzofuranyl Derivatives GCK, GCKR, GALK1 GCK 1/4885KCNH2 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.